Plus Therapeutics Inc Stock Price, News & Analysis

Plus Therapeutics, Inc. (Nasdaq: PSTV) announced that CEO Marc Hedrick will present at the 2022 Q2 Investor Summit on May 3, 2022, at 12:30 p.m. ET in New York. The company develops targeted radiotherapeutics for hard-to-treat cancers. Interested investors can arrange meetings with management at the event. A webcast of the presentation will be available on the Plus Therapeutics website, with a replay accessible for 90 days afterward. Plus Therapeutics focuses on innovative cancer treatments using a proprietary nanotechnology platform.

Plus Therapeutics (PSTV) announced the first patient dosing in the ReSPECT-LM Phase 1/2a trial of 186RNL for leptomeningeal metastases, highlighting a significant step in its drug development efforts. The company reported a cash balance of $21.2 million as of March 31, 2022, reflecting an increase from $18.4 million at year-end 2021. However, total operating expenses rose to $3.9 million, leading to a net loss of $4.1 million, or $(0.19) per share, for Q1 2022. Plus Therapeutics also expanded its partnership with Medidata to enhance trial efficiency, aiming for FDA approval for multiple upcoming trials.

Plus Therapeutics (PSTV) announced an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, scheduled for June 11-14, 2022, in Vancouver, Canada. The presentation will cover new data on Rhenium-186-NanoLiposome (186RNL) for treating relapse/recurrent glioblastoma (rGBM). The presentation will be available on the company's website post-event. Plus Therapeutics is focused on developing innovative cancer treatments utilizing a proprietary nanotechnology platform to enhance drug delivery and efficacy.

Plus Therapeutics (PSTV) will announce its Q1 2022 financial results on April 21, 2022, after market close. Following the release, the management team will host a conference call at 5:00 p.m. ET to discuss the results and provide updates on the company's progress. Investors can access the live broadcast and later replay via the Plus Therapeutics website. The company focuses on developing innovative, targeted radiotherapeutics for challenging cancer types, utilizing a proprietary nanotechnology platform for drug delivery and enhancement.

Plus Therapeutics (Nasdaq: PSTV) announced its participation at the AACR 2022 Annual Meeting, presenting a poster on a biology-based model predicting recurrent glioblastoma response to treatment with ¹⁸⁶Re-labeled nanoliposomes. The poster will be showcased on April 12, 2022, from 9:00 a.m. to 12:30 p.m. CT at the New Orleans Convention Center. Plus Therapeutics focuses on innovative cancer therapies using advanced nanotechnology for drug delivery. The company is committed to developing effective treatments for patients with difficult-to-treat cancers.

Plus Therapeutics (PSTV) announced an expanded partnership with Medidata to enhance its upcoming Phase 2 trial of Rhenium-186 NanoLiposome (186RNL) for recurrent glioblastoma. This collaboration aims to speed enrollment and reduce trial costs by utilizing Medidata's Synthetic Control Arm® platform, which incorporates historical clinical trial data, increasing patient access to innovative therapies. Dr. Norman LaFrance emphasized that this approach minimizes patient exposure to ineffective treatments. The partnership follows a successful feasibility phase, enhancing the trial's scientific validity.

Plus Therapeutics, Inc. (Nasdaq: PSTV) has announced that CEO Marc Hedrick will present at the 2022 Virtual Growth Conference from March 28-30, 2022. The conference will feature pre-recorded presentations available on-demand. Plus Therapeutics is focused on developing targeted radiotherapeutics for difficult-to-treat cancers, notably using Rhenium-186 NanoLiposome in clinical trials for recurrent glioblastoma. For more details, visit PlusTherapeutics.com.

Plus Therapeutics (PSTV) announced the initiation of the ReSPECT-LM Phase 1/2a clinical trial for Rhenium-186 NanoLiposome (186RNL), targeting leptomeningeal metastases (LM). The first patient has been dosed in this multicenter study, which evaluates safety, tolerability, and maximum tolerated/dose feasible doses of 186RNL. This treatment aims to address the unmet medical need for LM patients, who face poor survival rates and lack FDA-approved options. The FDA has granted Fast Track designation for 186RNL, allowing for expedited development and review.

Plus Therapeutics (Nasdaq: PSTV) is set to sponsor and present an industry satellite symposium titled Radiolabeled NanoLiposomes: A Novel Targeted Treatment for Rare and Central Nervous System Cancers at the Society of Nuclear Medicine and Molecular Imaging Therapeutics Conference from March 10-12, 2022, in New Orleans. The presentation will take place on March 12 at 7:15 a.m. CT, led by Chief Medical Officer Norman LaFrance. Plus Therapeutics focuses on developing radiotherapeutics, including its lead candidate, Rhenium-186 NanoLiposome, targeting recurrent glioblastoma.